Affinity Groups
There are no Affinity Groups associated with this topic. View All Affinity Groups.
Announcements
Title | Date |
---|---|
CI Pathways: Leading the Way to Effective CI Use | 02/20/25 |
Ookami Webinar | 02/14/24 |
Upcoming Events & Trainings
Title | Date |
---|---|
ACES: AI/ML TechLab on Intel PVC GPUs | 3/04/25 |
NAIRR Pilot Office Hours | 3/11/25 |
ACES: AI/ML TechLab on Graphcore IPUs | 3/18/25 |
Topics from Ask.CI
Loading topics from Ask.CI...
Knowledge Base Resources
Title | Category | Tags | Skill Level |
---|---|---|---|
Attention, Transformers, and LLMs: a hands-on introduction in Pytorch | Learning | aideep-learningmachine-learning +2 more tags | Intermediate |
DeepChem | Tool | pytorchtensorflowcomputational-chemistry | Beginner, Intermediate, Advanced |
fast.ai | Website | aimachine-learningpytorch +1 more tags | Beginner, Intermediate, Advanced |
Engagements

Re-engineering Lilly’s KisunlaTM into a novel antibody targeting IL13RA2 against GBM using AI-driven macromolecular modeling
Atrium Health Levine Cancer
- Summary and objectives of the proposed experiments:
- An initial research-based Ab (scFv47, discovered by our collaborator Dr. Balyasnikova) model, modeling Ab-Ag (IL13RA2 against GBM) protein complex, and identifying the binding sites (epitopes) using ROSETTA and AlphaFold2 multimer tools.
- Graft the CDRs of scFv (single-chain variable fragment) of antibody or Bispecific T cell engagers (BTEs) onto the template Ab, the framework of Lilly's Kisunla™ Ab drug.
- Modify, improve, and optimize the overall or full antibody protein structures using AI-driven macromolecule modeling (AlphaFold3).
- Explore single nucleotide polymorphism (SNP), pathogenic genetic variants and N-glycosylation of IL13RA2 (target) protein domain interacting with the Ab candidates among the patient population using ROSETTA software packages.
Status: In Progress